Aurobindo Pharma shares jumped more than 3.5% on Friday, February 16, after the pharma company said the United States Food and Drug Administration (USFDA) completed the inspection at the manufacturing unit of its synthetic peptides active pharmaceutical ingredient (API) business arm, Auro Peptides Ltd in Telangana.
The USFDA’s inspection had zero observations, Aurobindo Pharma said in a stock exchange filing.
Aurobindo Pharma said the US regulator conducted an audit at the Auro Peptides’ manufacturing unit from February 12 to February 16, 2024.
Article excerpt reposted from cnbctv18.com
Auro Peptides has filed ’14 US DMFs’, which have contributed to ‘5 ANDA approvals’ thus far.
